CD274 and cervical carcinoma: The National Comprehensive Cancer Network (NCCN) guidelines for cervical cancer (Version 1.2022) recommend pembrolizumab combined with chemotherapy as a first-line recommendation for patients with PD-L1 positive, recurrent, or metastatic cervical cancer.